Companion Diagnostics Market Size, Share, Growth Report 2032

According to the report published by Zion Market Research, the global Companion Diagnostics Market size was valued at USD 6.24 Billion in 2023 and is predicted to reach USD 22.09 Billion? by the end of 2032. The market is expected to grow with a CAGR of 15.08% during the forecast period. The report analyzes the global Companion Diagnostics Market ’s growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Companion Diagnostics Market industry.

Request Free Sample

Global Companion Diagnostics Market: Overview

A diagnostic test used as an associate to the therapeutic drug in order to determine its usefulness to the patient is known as companion diagnostics. This technology is useful for improving therapeutic treatment available based on the individual. Companion diagnostics integrate pharmacogenomic information that will assist to make most optimal treatment decision possible for the patient. Companion diagnostic is an in-vitro medical device that is used to provide information necessary for effective and safe use of the corresponding drug.

It will help healthcare professionals to determine whether therapeutic products benefit to patients or cause any side effects. It is gaining importance in the drug discovery and personalized treatment medicine. Companion diagnostic is also used to determine patient personal molecular profile to decide which therapy is useful for the patient. Companion diagnostics test finds the presence of a biomarker in the patient and its presence and absence will determine whether a patient will respond to the treatment or not.

Request Free Sample

Global Companion Diagnostics Market: Growth Factors

Escalating growth in the global companion diagnostics market is mainly due to technological development in the medical devices for the treatment and diagnosis of the patients. Increasing prevalence of diseases such as cancer & HIV is anticipated to foster the global market growth as it helps in determining patient-specific dose and drugs. Rising awareness among patients and physicians regarding drug toxicity is positively enhancing the global companion diagnostics market. Increasing population in the developing countries is expected to propel the global market growth. However, the major challenges before the global market are the lack of skilled professionals, lack of awareness about companion diagnostics, and logistic issues raised in order to develop drug and companion diagnostics together, which may hinder the global companion diagnostics market growth.

Global Companion Diagnostics Market: Segmentation

The global companion diagnostics market is segmented into its disease, indication and region.

Based on the disease as gastric cancer, colorectal cancer, melanoma cancer, genital cancer, breast cancer, lung cancer, and others.

On the basis of indications, the global market is segmented as inflammation, cardiovascular, virology, central nervous system, and oncology. Of these, oncology is the largest revenue-generating segment in the global companion diagnostics market.

Companion Diagnostics Market : Report Scope

Global Companion Diagnostics Market: Regional Analysis

The global companion diagnostics market is segmented based on geography as Europe, Asia Pacific, Latin America, North America, and the Middle East & Africa. North America contributed for the largest market chunk. Europe accounted for the largest market share in the global market owing to increasing incidence of cancer and other diseases. In addition, increasing healthcare awareness in this region also positively impacts the global companion diagnostics market.

Global Companion Diagnostics Market: Competitive Players

Major players denominating the global companion diagnostics market growth are:

• Myriad Genetics
• Qiagen
• Life Technologies
• Abbott
• Thermo Fischer Scientific
• Genomic Health.

Other players influencing the global market are:

• Roche Holdings
• Protagen Diagnostics
• Amgen
• Agilent Technologies
• Myriad Genetics
• Sysmex.

The Global Companion Diagnostics Market is segmented as follows:

By Disease 

• gastric cancer 
• colorectal cancer 
• melanoma cancer 
• genital cancer 
• breast cancer 
• lung cancer 
• and others 

By Indications 

• inflammation 
• cardiovascular 
• virology 
• central nervous system 
• oncology 

Global Companion Diagnostics Market: Regional Segment Analysis

• North America
  • U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

What Report Provides

• Full in-depth analysis of the parent market
• Important changes in market dynamics
• Segmentation details of the market
• Former, on-going, and projected market analysis in terms of volume and value
• Assessment of niche industry developments
• Market share analysis
• Key strategies of major players
• Emerging segments and regional markets
• Testimonials to companies in order to fortify their foothold in the market.